Vancouver, British Columbia–(Newsfile Corp. – February 2, 2021) – CVR Medical Corp. (TSXV: CVM) (OTC: CRRVF) (“CVR Medical” or the “Company” or “we“) a Canadian listed and US based healthcare company in the medical device market intends to diversify its’ Directors which is subject to approval at the Annual Shareholders’ Meeting. Harvey […]
Other News
Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development
WARRINGTON, Pa., Feb. 1, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Joseph Soffer, M.D., F.A.C.C., as Executive Director of Clinical Development, effective immediately. “We are thrilled to welcome Joe […]
BioSig and Mayo Clinic Collaborate on New R&D Program to Develop Transformative AI and Machine Learning Technologies for its PURE EP™ System
Westport, CT, Feb. 02, 2021 (GLOBE NEWSWIRE) — Global market for AI in healthcare is estimated to reach $45.2 billion by 2026 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full […]
AliveCor Now Detects Six Times as Many Cardiac Conditions as Any Other Personal ECG
Launch of expanded range of determinations cements AliveCor as the most comprehensive AI-enabled solution in personal ECG MOUNTAIN VIEW, Calif., Feb. 1, 2021 /PRNewswire/ — AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today launched an expanded range of ECG determinations on its KardiaMobile devices. These new determinations are cleared by […]
CardioFocus Announces Expanded Partnership With Japan Lifeline
HeartLight® X3 Japan Launch Anticipated in Mid-2021 MARLBOROUGH, Mass., Feb. 2, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced today that it has expanded its existing partnership agreement with Japan Lifeline Co., Ltd. (JLL). The agreement extends the timeframe of the existing distribution […]
JanOne Announces Closing of $6.0 Million Common Stock Offering
Net proceeds will help support planning of clinical trials for JAN101, the company’s lead drug candidate LAS VEGAS, Feb. 2, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities […]
Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This partnership brings together CSI’s leadership in the treatment of calcified arterial lesions with Dr. Philippe Marco, a pioneer […]
Neovasc Announces 2021 Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina
VANCOUVER and MINNEAPOLIS, MN, Feb. 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the German Institute for the Hospital Remuneration System(“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation once […]
Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants
Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its third annual Communications Fellowship Grant program, intended to support increased capacity in communications, awareness building and community engagement […]
BioCardia Update on Cell Therapy Product Development and 2021 Milestones
SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides an update on its cell therapy product development and 2021 milestones. BCDA-01, our CardiAMP autologous cell therapy under Phase III clinical development for the treatment of […]



